E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus
influenzae type b. |
|
E.1.1.1 | Medical condition in easily understood language |
Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus
influenzae type b. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that VaxemTM Hib given to children aged 13-59 months at study entry is non-inferior to comparator vaccine HIBERIX® with regard to percentage of subjects with antibody levels of ≥ 0.15μg/mL one month after vaccination as measured by anti- PRP ELISA. |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate percentage of subjects after immunization with Vaxem Hib in comparison with HIBERIX with regard to antibody levels of 1.0 micrograms/mL one month after vaccination as measured by anti-PRP ELISA. To evaluate Anti- PRP geometric mean concentration (GMC).
2. To compare safety and tolerability of one dose of Vaxem™Hib with the control one dose of HIBERIX® when given to children aged 13-59 months.
3. Determine incidence/percentage of subjects with local and/or systemic adverse reactions, adverse events (AEs), and serious adverse events (SAEs) after vaccination in each group. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. 13-59 months-old children;
2. in good health as determined by:
a. medical history
b. physical examination
c. clinical judgment of the investigator;
3. available for all visits scheduled in the study and able to comply with all study regulations;
4. written informed consent obtained, from at least one parent or legal guardian. |
|
E.4 | Principal exclusion criteria |
Subjects presenting any of the following will not be included in the study:
1. parent or legal guardian is unwilling or unable to give written informed consent to participate in study;
2. children who have received any other Haemophilus influenzae type b immunization dose before;
3. children who presented a previous disease potentially related to Haemophilus influenzae type b;
4. children who had household contact and/or intimate exposure in the previous 30days to an individual with ascertained invasive Haemophilus influenzae type b disease;
5. premature (before 37th week of gestation) or birth weight less than 2500 g;
6. history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
7. fever >=38.0 °C (axillary) and/or significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment;
8. subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease;
9. known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;
10. subjects with any neurological disorder, e.g. epilepsy or history of seizure disorder;
11. subjects with a clinically significant genetic anomaly;
12. treatment with corticosteroids or other immunosuppressive drugs;
13. any previous treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives;
14. any vaccination administered within one week (7 days) before enrollment and/ or any planned administration of any vaccine outside the Chinese routine vaccination program;
15. participation in any other investigational trial simultaneously;
16. planned surgery during the study period;
17. any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objective. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Percentages of subjects with anti-PRP-ELISA antibody levels ≥ 0.15 μg/mL. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. one month after booster vaccination. |
|
E.5.2 | Secondary end point(s) |
1. Percentages of subjects achieving an anti-PRP concentration ≥ 1.0 μg/mL;
2. Anti-PRP geometric mean concentration (GMC);
3. Number of subjects reporting local and systemic reactions up to 6 days post vaccination;
4. Number of unsolicited adverse events occurring throughout the study period. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 and 2. one month after booster vaccination;
3. up to 6 days post vaccination (safety endpoint);
4. throughout the study period (safety endpoints). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 7 |